Please assess the completion status of the following clinical trial:

Trial Title: HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males age 18-50~* Normal serum testosterone, LH and FSH~* PSA \< 4.0~* Agrees not to donate blood or participate in another research study during the study~* Informed consent~* In general good health based on normal screening evaluation (consisting of a medical history, physical exam, normal sperm count, normal serum chemistry and hematology)~* Must be willing to use a reliable form of contraception during the study~Exclusion Criteria:~* Oligospermia (sperm count \< 15 million/mL after 48 hours of abstinence) and/or abnormal motility or morphology.~* Participation in a long-term male contraceptive study within the past three months~* History of testosterone or anabolic steroid abuse in the past~* Poor general health with significantly abnormal blood results~* History of or current testicular disease~* History of a bleeding disorder or need for anticoagulation~* History of sleep apnea and/or major psychiatric problems~* BMI \> 32~* Subjects with a skin condition that might interfere or be exacerbated by testosterone gel use~* Subject's with alcohol or drug use

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Acyline plus Placebo (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 15 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 60 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus 125 IU hCG (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
- Acyline plus Testosterone gel (Type: EXPERIMENTAL): Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).